Cobro Ventures

NextRNA Therapeutics creates targeted therapeutics with the aim of discovering novel ncRNAs that cause disease. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.

WindGap Medical is a biotech company that manufactures medical devices used to treat patients with severe allergies. The company develops auto-injectors that are filled with heat-stable epinephrine that enable physicians to inject it into a patient suffering from anaphylaxis due to an acute allergy attack. The company was established in 2011 and is headquartered in Somerville, Massachusetts.

TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates. Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.

Educating Immune Cells, Eliminating Cancer. Our team of scientists, physicians, and advocates are passionate about one thing: harnessing our immune cells to combat cancer - conferring lifelong immunity to the disease. Meet the team charged with immune cell education and cancer elimination.

Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies.

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

Educating Immune Cells, Eliminating Cancer. Our team of scientists, physicians, and advocates are passionate about one thing: harnessing our immune cells to combat cancer - conferring lifelong immunity to the disease. Meet the team charged with immune cell education and cancer elimination.

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

Acetylon Pharmaceuticals, Inc. intends to manufacture small molecule drugs to realize the therapeutic potential of histone deacetylase. The company was incorporated in 2008 and is based in Boston, Massachusetts.

Founded in 1986, OPNET Technologies, Inc. (NASDAQ: OPNT) is a provider of software products and related services for managing networks and applications. Their products by focusing on analytics. Traditional application and network management products focus on data collection and monitoring. These systems typically report on historical trends and the status of networks and systems. They are limited by their lack of understanding of the underlying technologies that support applications, and the relationships among these technologies. While they provide useful information, they do not automate the next important step, which is analyzing collected data to transform it into actionable information. OPNET’s analysis capabilities drive the rapid resolution of performance problems, and also proactively prevent problems from occurring. These problems include, for example, network configuration errors, network congestion, poor interaction between the network and applications, inefficient use of the network by applications, application bugs, and database inefficiencies. They believe that OPNET’s analytics can significantly improve the performance and availability of mission-critical networks and applications.